Market Intelligence, Clinical Progress, and High-Purity Reagents for BET-Selective Oncology & Inflammation Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for BRD2 drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | BRD2 BD1/BD2 Domain Proteins & Full-Length Recombinant Protein (HEK293 expressed, >95% purity, Endotoxin <1EU/ug, Sequence Verified. Theoretical MW confirmed) | View BRD2 Products |
| Gene Delivery | BRD2 Promise-ORF / Lentivirus Full-length ORF for stable cell lines and overexpression studies. |
View BRD2 Products |
| Benchmark Ab | Anti-BRD2 (Research Grade Clone & Pan-BET Reference Standard) Recombinant positive control for Western/IF and isoform specificity testing. |
View BRD2 Products |
| Validator | BRD2 siRNA Set For knockdown verification, target engagement confirmation, and off-target screening. |
View BRD2 Products |
| Related Target: BRD4 | BRD4 Bromodomain Protein Primary off-target and safety counter-screen for BET selectivity. |
View BRD4 Products |
| Related Target: BRD3 | BRD3 Bromodomain Protein Bromodomain family homology; essential for isoform discrimination. |
View BRD3 Products |
| Related Target: MYC | MYC Transcription Factor Downstream oncogenic driver regulated by BET proteins for functional validation. |
View MYC Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| BET Family Selectivity (BRD2 vs BRD4/BRD3/BRDT) | Homolog panel proteins (BRD2, BRD3, BRD4, BRDT BD1/BD2) strictly verified by mass spec, >95% purity |
| Domain-Specific Inhibitor Screening (BD1 vs BD2) | Individual bromodomain truncations (BD1-only aa 1-170, BD2-only aa 348-455) with theoretical MW confirmed; suitable for SPR/BLI and TR-FRET |
| PROTAC Ternary Complex Formation & Degradation | Full-length BRD2 recombinant protein (endotoxin <1 EU/µg) for SPR/BLI; lentivirus for cellular NanoBRET/AlphaLISA target engagement |
| Resistance Mutation Analysis | BRD2 mutant recombinant proteins (e.g., equivalent to W370A, N433F) for acquired resistance mechanism studies |
| Lack of Controls & False Positives | Validated siRNA included for specificity checks; assay-ready reference compounds; sequence-verified antibodies for baseline normalization |
Live BRD2 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for BRD2 therapeutics is intensifying, with major players shifting focus from traditional pan-BET inhibitors to isoform-selective BRD2 ligands and degraders. First-generation pan-BET therapies (targeting BRD2/3/4) demonstrated efficacy in MYC-driven hematological malignancies but were limited by dose-limiting toxicities—thrombocytopenia linked to BRD4 inhibition and gastrointestinal adverse events. The next R&D wave is sharply pivoting towards BRD2-selective modulation and domain-specific (BD1 vs. BD2) strategies to decouple anti-tumor efficacy from safety liabilities. Expansion into inflammatory and metabolic indications is also emerging, driven by BRD2's role in NF-κB and cytokine regulation. As clinical programs mature, rigorous selectivity profiling—including orthogonal validation against both bromodomains, counter-screening against BRD4/BRD3, and resistance mutation modeling—has become essential for lead optimization.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule (Pan-BET Clinical Benchmark) | Bristol-Myers Squibb, Incyte, GlaxoSmithKline, Constellation | NUT Carcinoma, AML, Multiple Myeloma, Solid Tumors | Safety Profiling (Need BRD3/BRD4 homologs for off-target assessment) |
| Small Molecule (BRD2 Selective / BD2-Selective) | AbbVie, Forma Therapeutics, Roche, Zenith Epigenetics | Solid Tumors, Hematologic Malignancies, Inflammation | Domain Selectivity Assay (Need purified BD1 vs BD2 proteins; BRD2 vs BRD4 counter-screen) |
| PROTAC / Degrader | Arvinas, Dialectic Therapeutics, C4 Therapeutics, Academic Consortiums | Refractory Cancers, BRD2-Addicted Cancers | Ternary Complex SPR / Cellular Degradation Assay (Need full-length BRD2 + E3 ligase components; lentivirus for stable lines) |
| Dual-Inhibitor (e.g., PI3K/BET) & Peptide Ligands | Various Biopharma, Early-stage Biotech | Refractory Cancers, Inflammation | Cross-Pathway Validation (Need pure enzymes, siRNA, and high-purity individual bromodomains) |